2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, L3
Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company Focused on Plasma-Derived Therapies
Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Annual General Meeting of Shareholders on August 5, 2026
Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
Condensed Consolidated Interim Financial Statements as of March 31, 2026
To Announce First Quarter 2026 Financial Results on May 13, 2026
Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order